# Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

> **NCT05900921** · PHASE2 · UNKNOWN · sponsor: **Sichuan University** · enrollment: 132 (estimated)

## Conditions studied

- Advanced Squamous Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** Trilaciclib
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05900921
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-01
- **Primary completion:** 2024-10-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2023-06-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05900921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05900921, "Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05900921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*